Provider Reviews

Omzo vs Hers: Compounded Semaglutide vs Brand Wegovy Options

Omzo vs Hers is a choice between compounded medication access with clinician-guided plans and branded FDA-approved Wegovy with a personalized care team. Early verdict: choose Omzo if you want clinician-guided access to compounded semaglutide starting at $179; choose Hers if you prefer FDA-approved Wegovy from $149/mo and ongoing dose check-ins.

Explore Omzo clinician-guided plans

Key difference 1: Compounded medications versus FDA-approved brand

Omzo emphasizes a compounded medication program: compounded semaglutide and tirzepatide prepared by a state licensed sterile compounding pharmacy. The Omzo source explicitly states these compounded drugs are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness, or quality. By contrast, Hers highlights FDA-approved Wegovy, a brand-name semaglutide, and states it does not offer compounded medications.

Key difference 2: Pricing structure and starting costs

Both providers publish starting prices but with different structures. Omzo lists semaglutide starting at $179 and tirzepatide starting at $279, with medication costs included in fees collected by Omzo. Hers lists Wegovy from $149/mo and injectable from $199/mo, but notes an active Hers Weight Loss Membership is required and membership and medication are billed separately.

Key difference 3: Clinical model and follow up

Omzo connects users with licensed U.S. medical providers who determine eligibility and prescribe based on clinical judgment; Omzo is not a medical practice and clinical services are provided by third party networks. Hers promotes a personalized care team with ongoing dose check-ins and emphasizes doctor-trusted, FDA-approved options. Both note that treatment is available only when a licensed clinician determines it is medically appropriate.

Key difference 4: What you receive and who fills prescriptions

Omzo states its primary program provides access to compounded medications produced in FDA-registered facilities but not FDA-approved, and that if a branded medication is prescribed the patient is responsible for filling it at their chosen pharmacy. Hers provides brand-name Wegovy as an option and says name brand medication is not compounded.

Comparison table

Criteria Omzo Hers
Medication type Compounded semaglutide & tirzepatide (not FDA-approved) FDA-approved Wegovy and other brand GLP-1s, not compounded
Starting price Semaglutide starting at $179; tirzepatide starting at $279 Wegovy from $149/mo; injectable from $199/mo (medication only)
Clinical model Clinician-guided plans reviewed by licensed U.S. providers; third party networks Personalized care team with ongoing dose check-ins
Regulatory note Compounded medications are not FDA-approved Offers FDA-approved Wegovy; no compounded products
Membership/fees Medication costs included in Omzo fees; verify eligibility, renewal, state availability Active Hers Weight Loss Membership required; membership and medication billed separately

Other considerations from the sources

Omzo repeatedly notes results may vary, that it does not create a doctor patient relationship via its assessment, and that providers make the final determination to prescribe. It also states compounded medications offered by providers accessed through Omzo are produced in FDA-registered facilities but are not FDA-approved. Hers highlights that Wegovy and Zepbound are FDA-approved for weight loss and states that prescriptions are subject to clinician review and not available in all 50 states.

Safety and eligibility notes

Both sources emphasize eligibility is determined by a licensed clinician and that medication availability and state coverage may change. Omzo cautions that compounded drugs are not FDA-approved and have not been evaluated by the FDA for safety, effectiveness, or quality. Hers reiterates which branded options are FDA-approved and notes prescriptions require clinician determination.

Check Omzo eligibility and options

Final comparison and who each is best for

Omzo vs Hers comes down to a choice between compounded medication access and branded FDA-approved therapy with ongoing dose support. Omzo offers clinician-guided access to compounded semaglutide starting at $179 and tirzepatide starting at $279, while Hers offers FDA-approved Wegovy from $149/mo with a personalized care team and dose check-ins but requires an active membership for medication access.

Choose Omzo if…

  • You want clinician-guided access to compounded semaglutide or tirzepatide and accept that compounded medications are not FDA-approved.
  • You prefer medication costs included in fees collected through the Omzo program and want fast discreet delivery options as described by Omzo.

Choose Hers if…

  • You prefer FDA-approved brand-name Wegovy with a personalized care team and ongoing dose check-ins.
  • You accept a membership requirement and separate billing for medication as described by Hers.

When thinking about Omzo vs Hers, confirm eligibility, medication details, total cost, renewal terms, and state availability with each provider before enrolling.

Ready to Compare Telehealth Providers?

Explore leading providers — physician-supervised, all-inclusive pricing, and free home delivery.

Compare All Providers →

More comparisons

Provider ReviewsShed vs Omzo: Coaching and Compounded GLP-1 ComparedShed offers name-brand and compounded GLP-1 plus integrated coaching and a 2-minute assessment with 10% off first month; Omzo focuses on clinician-guided compounded care starting at $179.September 18, 2026Provider ReviewsOmzo vs Yucca Health: Price, meds, and speed comparedOmzo offers clinician-guided compounded semaglutide starting at $179. Yucca Health offers compounded semaglutide from $146/month and tirzepatide from $258/month.September 14, 2026Provider ReviewsOmzo vs YourEra: Clinician-Guided GLP-1 Care ComparedCompare Omzo and YourEra on price, compounded GLP-1 availability, clinician review, branded prescriptions, and shipping. Omzo starts at $179; YourEra from $99/mo.September 14, 2026Provider ReviewsJoinFridays vs Hers: Compounded Pricing vs FDA-Approved OptionsJoinFridays starts at $117/month with compounded tirzepatide and semaglutide, no long-term contracts. Hers offers FDA-approved Wegovy from $149/mo with a membership.September 9, 2026Provider ReviewsHumeCare+ vs Hers: Compounded Protocols vs FDA-Approved WegovyHumeCare+ bundles compounded semaglutide or tirzepatide with glycine, B12 and scans starting at $199/mo and a 10%-or-money-back promise; Hers offers FDA-approved Wegovy from $149/mo with a membership.September 8, 2026Provider ReviewsHers vs Wellorithm: Brand-name Wegovy vs Compounded GLP-1 OptionsHers offers FDA-approved Wegovy starting at $149/mo with a required membership and ongoing dose check-ins. Wellorithm offers compounded semaglutide from $147 and clinicians in all 50 states.September 8, 2026

Medical disclaimer: This page is for informational purposes only and is not medical advice. Always consult a licensed healthcare provider before starting any treatment. We may earn a commission from partner links on this page - see our advertising disclosure.